# Zoetis: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Zoetis Inc. · NYSE: ZTS · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/zoetis. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Zoetis: how the business works", with the page URL.

## The 30-second summary

Zoetis makes medicines, vaccines and diagnostic tests for pets and farm animals, and had revenue of $9.47 billion in FY2025. Vets, distributors and farmers buy them, and Zoetis kept $28.1 of every $100 as net income in FY2025. US companion animal revenue fell 8% in Q3 FY2026, and Zoetis lowered its FY2026 revenue guidance in May and again in August 2026.

## 5 points

- **What it sells:** Zoetis sells medicines, vaccines and diagnostic tests for animals, with revenue of $9.47 billion in FY2025; parasiticides were the largest category at $2.34 billion. [S4]
- **Who pays it:** In FY2025, pet products brought in 69.6% of Zoetis's revenue, farm-animal products 29.2% and contract manufacturing and human health 1.2%, mostly through vets and vet distributors. [S4]
- **What it keeps from $100:** Of every $100 that came in during FY2025, Zoetis kept $28.1 as net income after $7.2 of income tax and $2.3 of interest; items outside operations added only a net $36 million, and EBITDA (operating profit before depreciation and amortization) was $4.03 billion. [S4]
- **Where the operating profit comes from:** The United States segment earned $3,438 million of FY2025 segment earnings on $5,097 million of revenue, and International $2,264 million on $4,254 million. [S4]
- **The one thing to watch:** US companion animal revenue fell 8% in Q3 FY2026, while livestock revenue rose to $797 million from $746 million. [S13]

## What does Zoetis sell?

Zoetis makes medicines, vaccines and diagnostic tests for animals. Pets (dogs, cats, horses) brought in $6.59 billion of FY2025 revenue and farm animals $2.76 billion.

- **Parasiticides:** Treatments against fleas, ticks and worms, such as the monthly Simparica Trio chew for dogs. $2.34 billion of FY2025 revenue, the largest category. [S4]
- **Vaccines:** Vaccines for pets and farm animals. $1.96 billion of FY2025 revenue. [S4]
- **Dermatology:** Itch and allergy medicines for dogs, mainly the Apoquel tablet and the Cytopoint injection. $1.75 billion in FY2025. [S4]
- **Anti-infectives:** Antibiotics, mostly for farm animals, such as Draxxin for cattle and swine and the ceftiofur line. $1.04 billion in FY2025. [S4]
- **Pain and sedation:** Includes Librela for dogs and Solensia for cats, antibody shots for arthritis pain. $840 million in FY2025. [S4]
- **Diagnostics:** Tests and analyzers that vets use to find out what is wrong with an animal. $434 million in FY2025. [S4]

## Who pays Zoetis?

- **Pet owners, through vets (69.6% of revenue):** Medicines, vaccines and tests for dogs, cats and horses, usually bought by vets or vet distributors and sold on to owners. $6.59 billion in FY2025. [S4]
- **Livestock farmers (29.2% of revenue):** Products for cattle, swine, poultry, fish and sheep, sold to vets, farmers, distributors and retailers. $2.76 billion in FY2025. [S4]
- **Contract manufacturing and human health (1.2% of revenue):** Making products for other companies, plus some human health products. $116 million in FY2025. [S4]
- **Customer concentration:** largest customer 16.0% of revenue. The largest customer, a US veterinary distributor that Zoetis does not name, bought about 16% of FY2025 revenue. Zoetis gives no top-5 or top-10 customer share. [S4]

## Where the money went (FY2025)

1. Vets, distributors and farmers paid Zoetis $9.47 billion of revenue in FY2025.
2. Making the products cost $2.67 billion, leaving $6.80 billion of gross profit.
3. Selling and administration took $2.38 billion and research $698 million; amortization and restructuring took $179 million.
4. Interest cost $222 million, while other items added a net $36 million.
5. Income tax took $687 million, and $2.67 billion was left as net income.

Sources: S4.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31. — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 | 7,776 | 3,208 | 41.3% | 2,037 | 26.2% | 4.27 | 2,213 | 477 | 1,736 | S12 |
| FY2022 | 8,080 | 3,382 | 41.9% | 2,114 | 26.2% | 4.49 | 1,912 | 586 | 1,326 | S11 |
| FY2023 | 8,544 | 3,507 | 41.0% | 2,344 | 27.4% | 5.07 | 2,353 | 732 | 1,621 | S10 |
| FY2024 | 9,256 | 3,836 | 41.4% | 2,486 | 26.9% | 5.47 | 2,953 | 655 | 2,298 | S6 |
| FY2025 | 9,467 | 4,033 | 42.6% | 2,673 | 28.2% | 6.02 | 2,904 | 621 | 2,283 | S4 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

Net debt was $7.52 billion at Sep 30, 2026, about 1.9 times FY2025 EBITDA of $4.03 billion (Cityfort calculation from the Q3 FY2026 10-Q and the FY2025 10-K). [S1, S4, S6, S19, S20]

| Item | Value |
| --- | --- |
| Total debt | 9,049 |
| Cash and investments | 1,533 |
| Net debt (debt minus cash) | 7,516 |
| Net worth (shareholders' money) | 3,303 |
| Debt to equity (times) | 2.74 |

- Total debt of $9.05 billion is senior notes at carrying value: $750 million of 3.000% notes due 2027 is now current and $8.30 billion is long-term. Lease liabilities are left out.
- Cash of $1.33 billion plus $200 million of short-term investments is $1.53 billion, so net debt is $7.52 billion (Cityfort calculation from the Q3 FY2026 10-Q).
- Debt rose from $6.57 billion at Dec 31, 2024 to $9.04 billion at Dec 31, 2025. In 2025 Zoetis sold $1.85 billion of senior notes in August and $2.0 billion of 0.25% convertible notes due 2029 in December, and repaid $1.35 billion of notes.
- A $1.25 billion revolving credit line was undrawn at Sep 30, 2026, with no commercial paper outstanding.
- Shareholders' equity was $3.30 billion at Sep 30, 2026, against $4.77 billion at Dec 31, 2024; treasury stock (shares bought back) was $12.35 billion at cost.

## Who owns Zoetis? (as of Mar 20, 2026)

Each share has one vote and no holder controls Zoetis. The 22 directors and executive officers together held 912,848 shares, deferred units and exercisable options, about 0.2% of the 420.6 million shares at Mar 20, 2026 (Cityfort calculation from the 2026 proxy statement). [S18, S1]

- Officers and directors (as a group), shares: 0.2%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (407.49 million shares at Sep 30, 2026 (Q3 FY2026 10-Q), down from 424.93 million at Dec 31, 2025. It is the only class of stock.) | 407.49 | 1 | — | — | Yes | S1 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 11.36% | — | Jan 7, 2026 | Proxy figure from a Schedule 13G/A filed Jan 7, 2026 (47,778,909 shares at Dec 31, 2025). | S18 |
| BlackRock, Inc. | 8.68% | — | Jan 26, 2024 | Proxy figure from a Schedule 13G/A filed Jan 26, 2024 (36,492,748 shares at Dec 31, 2023), an older filing than Vanguard's. | S18 |

## What could go wrong

### A few products earn a large share of revenue

Simparica, Apoquel, Cytopoint, Librela and the ceftiofur line brought in about 42% of FY2025 revenue; the top ten about 57%. [S4]

What to watch: Dermatology and parasiticide sales each quarter

### Weaker demand and more competition in US pet products

US companion animal revenue fell 8% in Q3 FY2026. Zoetis cited price-sensitive pet owners, competition in dermatology and generic competition, and cut its FY2026 revenue guidance. [S13, S14]

What to watch: US companion animal revenue growth

### One distributor buys about a sixth of sales

The largest customer, an unnamed US veterinary distributor, bought about 16% of FY2025 revenue. [S4]

What to watch: The largest customer's share in the FY2026 10-K

### More debt after buybacks

Debt rose to $9.05 billion at Sep 30, 2026 from $6.57 billion at Dec 31, 2024, while shareholders' equity fell to $3.30 billion. $750 million of notes are due in 2027 and $2.0 billion of convertible notes in 2029. [S1, S6]

What to watch: Net debt and the Moody's and S&P ratings

### Securities class action

A class action filed in May 2026 alleges misleading statements about demand for four key products. Zoetis says it has substantial defenses; damages are not specified. [S1]

What to watch: Court rulings on the amended complaint

### Currency changes

About 42% of FY2025 revenue came in currencies other than the US dollar, mainly the euro, Brazilian real, Australian dollar, British pound, Canadian dollar and Chinese renminbi. [S4]

What to watch: Currency effects in each earnings release

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **Results against the FY2026 range:** In its Nov 5, 2026 earnings release, Zoetis said it expects FY2026 revenue of $9.220 to $9.320 billion and adjusted diluted EPS of $6.25 to $6.35. FY2025 revenue was $9.47 billion.
- **US pet product sales:** US companion animal revenue fell 8% in Q3 FY2026. Pet products were 69.6% of FY2025 revenue.
- **Dermatology against the new pain shots:** Dermatology sales were $1.15 billion in the first nine months of FY2026, against a recast $1.32 billion. In Q3 FY2026 the longer-acting Lenivia launched in Great Britain and Portela won Swiss approval.
- **Debt and buybacks:** $750 million of notes due 2027 are now current, and $770 million was left under the buyback program at Sep 30, 2026. Net debt was $7.52 billion on that date.
- **The class action:** A securities class action filed on May 27, 2026 alleges misleading statements about demand for four key products; an amended complaint followed on Oct 23, 2026. Zoetis says it has substantial defenses.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000050/0001555280-26-000050-index.htm (published Nov 5, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000040/0001555280-26-000040-index.htm (published Aug 6, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000024/0001555280-26-000024-index.htm (published May 7, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/0001555280-26-000011-index.htm (published Feb 12, 2026)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528025000274/0001555280-25-000274-index.htm (published Nov 4, 2025)
- S6: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528025000102/0001555280-25-000102-index.htm (published Feb 13, 2025)
- S7: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528024000332/0001555280-24-000332-index.htm (published Nov 4, 2024)
- S8: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528024000299/0001555280-24-000299-index.htm (published Aug 6, 2024)
- S9: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528024000249/0001555280-24-000249-index.htm (published May 2, 2024)
- S10: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528024000143/0001555280-24-000143-index.htm (published Feb 13, 2024)
- S11: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528023000074/0001555280-23-000074-index.htm (published Feb 14, 2023)
- S12: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528022000078/0001555280-22-000078-index.htm (published Feb 15, 2022)
- S13: Zoetis Q3 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000048/exhibit99q32026.htm (published Nov 5, 2026)
- S14: Zoetis Q2 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000038/exhibit99q22026.htm (published Aug 6, 2026)
- S15: Zoetis Q1 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/exhibit99q12026.htm (published May 7, 2026)
- S16: Zoetis Q4 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000008/exhibit9912-31x25q4.htm (published Feb 12, 2026)
- S17: Zoetis Q4 FY2024 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528025000100/exhibit9912-31x24q4.htm (published Feb 13, 2025)
- S18: Zoetis 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000015/zts-20260406.htm (published Apr 8, 2026)
- S19: Zoetis 8-K: convertible senior notes and capped calls (Dec 18, 2025). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000119312525324853/d35588d8k.htm (published Dec 18, 2025)
- S20: Zoetis 8-K: senior notes issue and redemption (Aug 27, 2025). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000119312525189772/d24666d8k.htm (published Aug 27, 2025)
- S21: Zoetis 8-K: new director (Oct 13, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000044/exhibit9912026newdirectork.htm (published Oct 13, 2026)
- S22: Zoetis Q3 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1555280/000155528025000272/exhibit99q32025.htm (published Nov 4, 2025)
